DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Novartis
Fusion Pharmaceuticals Inc.
AHS Cancer Control Alberta
Orano Med LLC
Sichuan Huiyang Life Science and Technology Corporation
Radionetics Oncology
Fore Biotherapeutics
University of Kentucky
University of Pennsylvania
Eli Lilly and Company
University of Cincinnati
Icahn School of Medicine at Mount Sinai
INSYS Therapeutics Inc
National Cancer Institute (NCI)